I'm 28, dying, and need £320,500 to spend more time with my son

I am just savouring every moment I have with Teddy ‘Good morning world’. It’s how my 5‑year‑old son Teddy and I greet the day, every day. Then, on his walk to school, we’ll pick three things we can see a tree, a car, a postman and spend the 10‑minute journey making up a story about them. When I pick him up for the day, he’ll beam as he shows me the pictures he’s drawn; ones of him, his mummy and his daddy. He’ll tell me proudly about winning the head teacher’s award. And that night, after I’ve read him a book and kissed his forehead, I’ll say to him ‘I love you more than all the stars in the sky, and deeper than the ocean’. He says it back before falling asleep. This may sound like an ordinary day but, to me, days like these are exceptional. I am fighting with everything I have to make sure I have more of them.

The headline of this story is a number, £320,500, a sum that feels like an impossible mountain for a 28‑year‑old mother to climb. It is, however, the price of a clinical trial that could buy her an extra five years to watch Teddy grow. In June 2026 she was diagnosed with incurable brain cancer. The doctors told her she had five years, but the only realistic hope lies in a trial that is out of reach for most families. Her partner Mason and her mother are already stretched thin, and the financial strain threatens to eclipse the emotional toll of her illness.

The first sign was a headache so intense it felt like a weight on top of her head. She described it as the worst she’d ever had, followed by confusion and an almost surreal moment when a football fell out of her mother’s boot and she didn’t notice. Her GP initially blamed dehydration, a misdiagnosis that could have delayed treatment by days. Her sister Brooke insisted on an A&E visit, and after nine hours she was finally seen. The radiographer’s face gave it away, something was seriously wrong. An MRI confirmed brain cancer, a verdict that turned her life from normal to a frantic race against time.

Everyone loves a good story about a clinical trial, a last‑ditch hope that turns a bleak diagnosis into a possibility. But the reality is that hope carries a price. The trial’s cost is not just the money, it is the emotional labor of fundraising, the anxiety of waiting for results, and the looming possibility that the money raised may still fall short. Her plea to “Help Jaimee reach her goal” (the article mistakenly uses Jaimee instead of her own name) underscores the desperation: £320,500 in three weeks. It is a figure that feels like a wall, not a bridge.

When we look at the broader context of medical research, the story of this mother is not unique. In the UK, many life‑saving trials are funded by a mix of public money, private donations, and patient contributions. Yet the public purse often covers only the research itself, not the patient’s out‑of‑pocket expenses. The implicit message is that innovation is a public good, but the burden of proof, the proof that you can actually afford to participate, falls on the patient. This creates a moral hazard: people who can’t afford the trial are effectively excluded from the benefits of cutting‑edge science.

I predict that by the end of 2027, the UK government will face mounting pressure to introduce a “clinical trial insurance” scheme, ensuring that patients are not left to shoulder the cost of trials that could extend their lives. If this happens, stories like hers will shift from personal appeals to systemic failures.

The narrative is clear: a young mother, a son, a looming cancer diagnosis, and a trial that could change their lives. But the underlying issue is how society values health equity. If a mother has to scramble for £320,500 to buy a few more years, what does that say about the safety net we have for the rest of us? It forces us to ask whether we are willing to let a single person’s story dictate the pace of medical progress.

The story ends on a note of hope, a clinical trial that could buy more time, but it also leaves a stark reminder that hope can be expensive. The next step, for her, for her son, and for the nation, is to ensure that hope is not a luxury only the affluent can afford.